|
Synonyms: DSP-3235 | KWA 0711 | KWA-0711 | KWA0711
Compound class:
Synthetic organic
Comment: Mizagliflozin is a novel orally bioavailable and selective sodium glucose co-transporter 1 (SGLT1) inhibitor. It acts locally in the intestinal lumen to block postprandial glucose absorption. It increases luminal water and is proposed to loosen stools [3,5].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Fukudo S, Kaku K. (2019)
Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation. J Neurogastroenterol Motil, 25 (2): 332-333. [PMID:30982244] |
|
2. Fukudo S, Kaku K. (2019)
Future Possibility of Mizagliflozin on Functional Constipation and/or Irritable Bowel Syndrome With Constipation. Gastroenterology, 157 (3): 898-899. [PMID:31228444] |
|
3. Inoue T, Takemura M, Fushimi N, Fujimori Y, Onozato T, Kurooka T, Asari T, Takeda H, Kobayashi M, Nishibe H et al.. (2017)
Mizagliflozin, a novel selective SGLT1 inhibitor, exhibits potential in the amelioration of chronic constipation. Eur J Pharmacol, 806: 25-31. [PMID:28410751] |
|
4. Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. (2019)
Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol, 4 (11): 831-844. [PMID:31474542] |
|
5. Spiller R. (2018)
Inhibiting glucose absorption to treat constipation. Lancet Gastroenterol Hepatol, 3 (9): 588-589. [PMID:30056027] |
|
6. (2018)
Correction to Lancet Gastroenterol Hepatol 2018; 3: 603-13. Lancet Gastroenterol Hepatol, 3 (9): e4. [PMID:30102185] |